LRMR
Larimar Therapeutics, Inc.
Healthcare — Biotechnology
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Strong Buy
1.2 / 5
10 analysts
$3.06
$-0.13 (-4.23%)
Target:
$14.40
(370.6%)
Price History
52-Week Range
Sign in to add LRMR to a watchlist or set price alerts.
Fundamentals
| Market Cap | $396.83M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.24 |
| EPS (TTM) | $-2.12 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -109.83% |
| Debt/Equity | 2.39 |
| Recommendation | Strong Buy 1.2 |
| Analyst Target | $14.40 |
| Analysts | 10 |
| Next Earnings | Aug 4, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 54.0 |
| Beta | 0.84 |
| SMA 20 | $3.80 |
| SMA 40 | $3.62 |
| 52-Week High | $6.42 |
| 52-Week Low | $2.72 |
| 50-Day Avg | $3.58 |
| 200-Day Avg | $3.90 |
| Avg Volume | $2.19M |
| Volume | 994.7K |
Performance Analysis
BULLISHLRMR shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($2.71), which could present a value opportunity.
~
RSI at 54.0 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Wall Street consensus is "Strong Buy" from 10 analysts.
+
Average analyst target of $14.40 implies 370.6% upside.
Recent News
Loading news...
Last updated: Aug 01, 2026 04:13 UTC
Back to Screener Export Report